Eli Lilly and Company $LLY Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.6% during the fourth quarter, Holdings Channel reports. The fund owned 154,504 shares of the company’s stock after purchasing an additional 10,876 shares during the quarter. ProShare Advisors LLC’s holdings in Eli Lilly and Company were worth $166,042,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Warner Group LLC boosted its stake in shares of Eli Lilly and Company by 0.7% during the fourth quarter. Warner Group LLC now owns 1,914 shares of the company’s stock valued at $2,057,000 after acquiring an additional 14 shares during the last quarter. L.K. Benson & Company P.C. purchased a new position in Eli Lilly and Company during the fourth quarter worth about $204,000. Cedar Wealth Management LLC lifted its position in Eli Lilly and Company by 80.2% during the fourth quarter. Cedar Wealth Management LLC now owns 474 shares of the company’s stock worth $509,000 after buying an additional 211 shares during the period. Envestnet Portfolio Solutions Inc. lifted its position in Eli Lilly and Company by 21.5% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 56,034 shares of the company’s stock worth $60,211,000 after buying an additional 9,906 shares during the period. Finally, Gambit Capital Management LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth about $26,541,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $988.76 on Tuesday. The stock’s 50-day moving average is $940.00 and its 200-day moving average is $999.39. The company has a market cap of $931.15 billion, a price-to-earnings ratio of 35.12, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the firm earned $3.34 earnings per share. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Zacks Research downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Finally, Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,218.33.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor enthusiasm remains supported by Eli Lilly’s powerful obesity and diabetes drug franchise, with articles highlighting surging Mounjaro/Zepbound demand and expectations for continued growth. Article Title
• Positive Sentiment: Recent business momentum is still very strong, with second-quarter-level commentary pointing to major sales growth and raised revenue expectations that reinforce the company’s long-term earnings power. Article Title
• Neutral Sentiment: Eli Lilly said it will participate in Bernstein’s Strategic Decisions Conference on May 28, which could give investors updated strategic and pipeline commentary, but the event itself is not a major near-term catalyst. Article Title
• Neutral Sentiment: Healthcare stocks were broadly stronger late Monday, which may have helped support LLY alongside the sector, but this looks like a market-wide move rather than a company-specific driver. Article Title
• Negative Sentiment: The Supreme Court’s refusal to hear Lilly’s challenge keeps a Medicaid fraud verdict alive, reinforcing litigation risk and potentially raising concerns about future government-rebate disputes and legal expenses. Article Title
• Negative Sentiment: Competition in obesity treatment remains intense, with Citi data suggesting Novo Nordisk’s Wegovy pill still has a strong prescription lead over Lilly’s rival programs, which could temper near-term excitement around Lilly’s market share gains. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.